March 19, 2018 / 8:50 PM / 9 months ago

BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi

March 19 (Reuters) - Astellas Pharma Inc:

* U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

* ASTELLAS PHARMA INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE ASSIGNED BY FDA IS JULY 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below